MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas

Targeted therapy has become a cornerstone for the treatment of melanoma patients. Targeting NRAS function is particularly challenging. To date, only single MEK inhibitor treatment was able to show minimal clinical efficacy. The discovery that co-targeting of MEK and CDK4,6 has antitumor activity cre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Posch, Christian, Sanlorenzo, Martina, Ma, Jeffrey, Kim, Sarasa T., Zekhtser, Mitchell, Ortiz-Urda, Susana
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2018
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201855/
https://ncbi.nlm.nih.gov/pubmed/30405888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26204
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller